Afatinib Dimaleate

马来酸阿法替尼

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameAfatinib Dimaleate
Drug Alias NameafatinibafatinibumGilotrifGiotrifTovok +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR L858R inhibitorsEGFR 19del inhibitorsEpidermal growth factor receptor erbB1 inhibitors +[5] 
TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2 +[5] 
Therapy Area/IndicationsPenile Squamous Cell CarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[35] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryUnited States
Original Approved Date2013/07/12
Country/TerritoryCzechiaBelgiumCanada +[55] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgShanghai Jiao Tong University School of MedicineBoehringer Ingelheim Pharma Gmbh & Co Kg +[13] 
Inactive CompaniesDana-Farber Cancer InstituteOtto Von Guericke University MagdeburgInstituto Nacional De Cancerologia +[10] 
Active IndicationsSolid tumoursUterine NeoplasmsCarcinoma, Non-Small-Cell Lung +[15] 
Inactive IndicationsPenile Squamous Cell CarcinomaGastroesophageal Junction NeoplasmsRenal Insufficiency +[20] 

Other Information

ATC CodeL01EB03
Related LinksWikipediaDrugBankKEGG